Fortrea Completes Acquisition of the Early Phase Services Division from Worldwide Clinical Trials
Key Highlights
- ➤Fortrea completes Worldwide Clinical Trials division acquisition in approximately $45 million all-cash transaction
- ➤Fortrea adds 200-bed GCP-compliant clinical pharmacology unit in San Antonio, Texas
- ➤Fortrea expands early-phase capacity to more than 570 beds globally
- ➤Fortrea adds 60,000-square-foot GLP-compliant Austin bioanalytical laboratory and biospecimen storage facility
- ➤Fortrea and Worldwide Clinical Trials establish agreements supporting client, employee and program continuity
Expert Statements
Anshul Thakral, CEO of Fortrea
“Completing this acquisition further strengthens our integrated, scalable and scientifically differentiated clinical development platform”
Anshul Thakral, CEO of Fortrea
“This transaction demonstrates tangible progress in Fortrea’s return to growth as we invest in our ability to win new opportunities and create lasting value for clients.”
Anshul Thakral, CEO of Fortrea
“By bringing together complementary clinical pharmacology and bioanalytical capabilities, we expect to expand the speed, flexibility and talent we can offer clients as they advance increasingly complex development programs.”
Anshul Thakral, CEO of Fortrea
“We are pleased to welcome the Early Phase Services team to Fortrea and look forward to delivering a seamless experience for clients, volunteers and the patients we ultimately serve.”
Scott Dove, Ph.D., president, Clinical Pharmacology Services at Fortrea
“With this investment, Fortrea adds capability and capacity in its commitment to help clients design and execute early development programs with greater speed, scientific rigor and operational connectivity.”
Scott Dove, Ph.D., president, Clinical Pharmacology Services at Fortrea
“The addition of dedicated bioanalytical capabilities and expanded CRU capacity gives our teams more ways to support both simple and complex studies, streamline execution and generate high-quality data that inform development decisions.”
Highlights * Fortrea completes acquisition of the Early Phase Services division from Worldwide Clinical Trials * Adds a 60,000-square-foot GLP-compliant bioanalytical laboratory in Austin, Texas; a 200-bed GCP-compliant clinical pharmacology unit in San Antonio, Texas; and a biospecimen storage facility in Pflugerville, Texas * Expands Fortrea’s early clinical development capacity to more than 570 beds globally and adds dedicated large and small molecule bioanalytical capabilities * Enables more integrated execution of early-phase studies by reducing operational handoffs between clinical and bioanalytical functions * Strengthens Fortrea’s end-to-end clinical development platform supporting clients from first-in-human studies through Phase IV and post-approval evidence generation * Supports Fortrea’s growth strategy by scaling early clinical development capabilities, increasing clinical research unit capacity and enhancing the company’s ability to create long-term value for shareholders * Provides continuity of operations, study delivery and client support throughout the transition through a strategic alliance agreement between the companies DURHAM, N.C., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (“CRO”), today announced it has completed its acquisition of the Early Phase Services division from Worldwide Clinical Trials. The division consists of a Clinical Research Unit (“CRU”) and Bioanalytical Laboratory operations, in an all-cash transaction valued at approximately $45 million.
Get started
Create a free account to read the full story.